Company Analysis Oscar Health, Inc.
1. Summary
Advantages
- Price (15.43 $) is less than fair price (17.81 $)
- The stock's return over the last year (-8.13%) is higher than the sector average (-15.59%).
- The company's current efficiency (ROE=-33.67%) is higher than the sector average (ROE=-82.41%)
Disadvantages
- Dividends (0%) are below the sector average (1.3%).
- Current debt level 8.89% has increased over 5 years from 0%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Oscar Health, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.5% | -13.2% | -3.2% |
| 90 days | -8.3% | -16.1% | -7.4% |
| 1 year | -8.1% | -15.6% | 9.7% |
OSCR vs Sector: Oscar Health, Inc. has outperformed the "Healthcare" sector by 7.46% over the past year.
OSCR vs Market: Oscar Health, Inc. has significantly underperformed the market by -17.87% over the past year.
Stable price: OSCR is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: OSCR with weekly volatility of -0.1563% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (15.43 $) is lower than the fair price (17.81 $).
Price not significantly lower than the fair price: The current price (15.43 $) is slightly lower than the fair price by 15.4%.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (114.26).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (73.51).
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.55) is lower than that of the sector as a whole (9.02).
P/BV vs Market: The company's P/BV (2.55) is lower than that of the market as a whole (22.32).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.3501) is lower than that of the sector as a whole (4.1).
P/S vs Market: The company's P/S indicator (0.3501) is lower than that of the market as a whole (15.92).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.04) is lower than that of the sector as a whole (17.72).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.04) is lower than that of the market as a whole (22.62).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -6.7% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-6.7%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-50.52%).
5.4. ROE
ROE vs Sector: The company's ROE (-33.67%) is higher than that of the sector as a whole (-82.41%).
ROE vs Market: The company's ROE (-33.67%) is lower than that of the market as a whole (25.01%).
5.5. ROA
ROA vs Sector: The company's ROA (-8.06%) is lower than that of the sector as a whole (6.75%).
ROA vs Market: The company's ROA (-8.06%) is lower than that of the market as a whole (6.62%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.3%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 13.11.2024 | Thrive Partners VII Growth GP, Director |
Purchase | 13.74 | 4 927 420 | 358 619 |
| 13.11.2024 | Kushner Joshua Co-Founder and Vice Chairman |
Purchase | 13.74 | 4 927 420 | 358 619 |
| 12.11.2024 | Thrive Partners VII Growth GP, Director |
Purchase | 13.68 | 5 756 800 | 420 819 |
| 11.11.2024 | Thrive Partners VII Growth GP, Director |
Purchase | 13.58 | 3 748 620 | 276 040 |
| 05.09.2023 | Sankaran Sid Director |
Sale | 6.25 | 872 719 | 139 635 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
